Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.
2.
3.

[Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].

Hu XX, Li L, Li DR, Zhang W, Cheng XQ, Zhang JQ, Tang BJ.

Ai Zheng. 2004 Oct;23(10):1194-8. Chinese.

PMID:
15473934
5.

Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis.

Katayama A, Bandoh N, Kishibe K, Takahara M, Ogino T, Nonaka S, Harabuchi Y.

Clin Cancer Res. 2004 Jan 15;10(2):634-40.

6.

Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer.

Schwandner O, Schlamp A, Broll R, Bruch HP.

Int J Colorectal Dis. 2007 Feb;22(2):127-36. Epub 2006 Aug 2.

PMID:
16896992
8.

[mRNA expression analysis of metastatic markers in clear-cell renal cell carcinoma].

Struckmann K, Mertz K, Staller P, Krek W, Schraml P, Moch H.

Verh Dtsch Ges Pathol. 2005;89:178-83. German.

PMID:
18035688
10.

[Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].

Wei QY, Wu YQ, Fan SQ.

Hunan Yi Ke Da Xue Xue Bao. 2003 Jun;28(3):212-6. Chinese.

PMID:
14653069
11.
12.

Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis.

Misugi F, Sumi T, Okamoto E, Nobeyama H, Hattori K, Yoshida H, Matsumoto Y, Yasui T, Honda K, Ishiko O.

Int J Mol Med. 2005 Oct;16(4):541-6.

PMID:
16142384
13.

Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in renal cell carcinoma.

Qiao ZK, Li YL, Lu HT, Wang KL, Xu WH.

World J Surg Oncol. 2013 Jan 3;11:1. doi: 10.1186/1477-7819-11-1.

14.

Tumor progression driven by pathways activating matrix metalloproteinases and their inhibitors.

Bodnar M, Szylberg Ł, Kazmierczak W, Marszalek A.

J Oral Pathol Med. 2015 Jul;44(6):437-43. doi: 10.1111/jop.12270. Epub 2014 Sep 22.

PMID:
25244188
15.

Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.

Gouyer V, Conti M, Devos P, Zerimech F, Copin MC, Créme E, Wurtz A, Porte H, Huet G.

Cancer. 2005 Apr 15;103(8):1676-84.

16.

Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer.

Kanayama H, Yokota K, Kurokawa Y, Murakami Y, Nishitani M, Kagawa S.

Cancer. 1998 Apr 1;82(7):1359-66.

PMID:
9529029
17.

[Expression and significance of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase in non-melanoma skin cancer].

Fu XR, Zhang C, Chen CY, Zhang L, Wang LX, Wang BH, Liu XY, Zhang MZ.

Zhonghua Zhong Liu Za Zhi. 2012 May;34(5):369-73. doi: 10. 3760/cma.j.issn.0253-3766.2012.05.011. Chinese.

PMID:
22883459
18.

Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.

Ylisirniö S, Höyhtyä M, Turpeenniemi-Hujanen T.

Anticancer Res. 2000 Mar-Apr;20(2B):1311-6.

PMID:
10810441

Supplemental Content

Support Center